Vaccine Effectiveness Against Anal HPV Among Men Who Have Sex With Men Aged 18-45 Years Attending Sexual Health Clinics in 3 United States Cities, 2018-2023.

Details

• Alternative Title:
  The Journal of Infectious Diseases, 2025, v. 231, no. 3: Vaccine Effectiveness Against Anal HPV Among Men Who Have Sex With Men Aged 18-45 Years Attending Sexual Health Clinics in 3 United States Cities, 2018-2023.
• Journal Article:
  The Journal of Infectious Diseases
• Personal Author:
  DeSisto, Carla L. ; Winer, Rachel L. ; Querec, Troy D. ; Dada, Damilola ; Pathela, Preeti ; Asbel, Lenore ; Lin, John ; Tang, Jennifer ; Iqbal, Alfred ; Meites, Elissa ; Unger, Elizabeth R. ; Markowitz, Lauri E.
• Description:
  We assessed human papillomavirus (HPV) vaccine effectiveness (VE) against anal HPV among men who have sex with men (MSM) in 2018-2023.
  
  Residual anal specimens from MSM without HIV aged 18-45 years were tested for HPV. We calculated adjusted prevalence ratios (aPR) and 95% confidence intervals (CI) for associations between vaccination (≥1 dose) and quadrivalent vaccine (4vHPV)-type prevalence adjusting for city, race/ethnicity, and nonvaccine-type HPV prevalence, stratified by age group (18-26, 27-45 years). VE was calculated as (1 - aPR) × 100.
  
  Among 2802 persons aged 18-26, 4vHPV-type prevalence was lower in those vaccinated at age <18 (aPR = 0.13; 95% CI, .08-.22; VE = 87%) and those vaccinated ≥2 years before specimen collection (aPR = 0.52; 95% CI, .42-.64; VE = 48%) compared with unvaccinated persons. Among 3548 persons aged 27-45, 4vHPV-type prevalence was lower in those vaccinated at ages 18-26 (aPR = 0.68; 95% CI, .57-.82; VE = 32%) and those vaccinated ≥2 years before specimen collection (aPR = 0.66; 95% CI, .57-.77; VE = 33%) compared with unvaccinated persons. While we observed no VE in persons vaccinated at age >26 overall, 4vHPV-type prevalence was lower in the subgroup vaccinated ≥2 years before specimen collection (aPR = 0.71; 95% CI, .56-.89; VE = 29%).
  
  We found high VE against anal 4vHPV-type prevalence among MSM aged 18-26 who were vaccinated at age <18. Lower VE was observed among MSM aged 27-45 who were vaccinated at age 18-26 or ≥2 years before specimen collection. While ideally vaccination should be given at younger ages, vaccination can prevent some future infections in this population.
• Content Notes:
  Author manuscript
• Subjects:
  • Humans
  • Male
  • Adult
  • Papillomavirus Infections
  • Young Adult
  • Adolescent
  • Middle Aged
  • Homosexuality, Male
  • Papillomavirus Vaccines
  • Anal Canal
  More +
• Keywords:
  • papillomavirus vaccines
  • papillomavirus infections
  • sexual and gender minorities
  • vaccination
• Source:
  The Journal of Infectious Diseases, 2025, v. 231, no. 3
• DOI:
  https://doi.org/10.1093/infdis/jiae394
• ISSN:
  0022-1899 ; 1537-6613
• Pubmed ID:
  39122662
• Pubmed Central ID:
  PMC11878371
• Document Type:
  Text
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/ ; CK14-140105PPHF18/CC/CDC HHSUnited States/
• Genre:
  Journal Article
• Place as Subject:
  United States ; Cities
• Pages in Document:
  751-761 (21 pdf pages)
• Volume:
  231
• Issue:
  3
• Download URL:
  https://stacks.cdc.gov/view/cdc/262056/cdc_262056_DS1.pdf
• File Type:
  [PDF - 208.59 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:6c40078a4a8e67538a4484641d97dfcd2de56e2639f4e852bd0d9bfd8268e49dd367669c26f688ec9bcf6356d93fd3d62d6222bc44bc7975c1c1d709a772c3ab